The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
Shyam A PatelPublished in: British journal of haematology (2024)
As we commemorate 50 years since the introduction of classical 7 + 3 induction chemotherapy for acute myeloid leukaemia (AML), we also embark upon new territory with the advent of novel targeted therapeutics, including BH3 mimetics. To date, we do not have much large-scale longitudinal data regarding the toxicities of such novel therapies. Johnson et al. perform a comprehensive analysis of cardiac toxicities with hypomethylating agents and venetoclax and offer valuable insight into risk-benefit analysis when considering front-line therapy for AML. Commentary on: Johnson et al. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. Br J Haematol 2024;204:1232-1237.
Keyphrases
- acute myeloid leukemia
- liver failure
- respiratory failure
- left ventricular
- newly diagnosed
- dendritic cells
- bone marrow
- drug induced
- aortic dissection
- chronic lymphocytic leukemia
- heart failure
- allogeneic hematopoietic stem cell transplantation
- small molecule
- risk factors
- hepatitis b virus
- drug delivery
- atrial fibrillation
- cancer therapy
- cross sectional
- squamous cell carcinoma
- big data
- intensive care unit
- machine learning
- acute lymphoblastic leukemia
- electronic health record
- artificial intelligence
- radiation therapy
- extracorporeal membrane oxygenation
- rectal cancer